Kim Alexander Y, Frantz Shelby, Krishnan Pranay, DeMulder Danielle, Caridi Theresa, Lynskey George Emmett, Spies James B
Department of Radiology, Division of Interventional Radiology, Medstar Georgetown University Hospital, NW, Washington, DC, United States of America.
PLoS One. 2017 Sep 1;12(9):e0183861. doi: 10.1371/journal.pone.0183861. eCollection 2017.
To review the initial imaging responses after drug-eluting embolic trans-arterial chemoembolization (DEE-TACE) delivered with the Surefire Infusion System ® for the treatment of hepatocellular carcinoma (HCC).
Single center retrospective evaluation of patients who underwent DEE-TACE for HCC, delivered with SIS. Information was gathered from available medical records. Treatment response rates were assessed using the modified Response Evaluation Criteria in Solid Tumors criteria. Assessment of adverse events was categorized per Common Terminology Criteria for Adverse Events version 4.03.
Twenty-two patients with 39 hepatocellular carcinoma lesions were treated with the surefire infusion system. Complete response was demonstrated in 32% of patients and 54% of lesions after a single treatment session. Overall disease response was demonstrated in 91% of patients and 85% of lesions after a single treatment. No grade 3 or higher elevations in liver function tests were demonstrated in the short-term.
SIS delivered DEE-TACE leads to a higher than expected initial response in patients with HCC.
回顾使用Surefire输液系统®进行药物洗脱栓塞经动脉化疗栓塞术（DEE-TACE）治疗肝细胞癌（HCC）后的初始影像反应。
对接受使用SIS进行DEE-TACE治疗的HCC患者进行单中心回顾性评估。从可用的病历中收集信息。使用改良的实体瘤疗效评价标准评估治疗反应率。根据不良事件通用术语标准4.03版对不良事件进行分类评估。
22例患有39个肝细胞癌病灶的患者接受了Surefire输液系统治疗。单次治疗后，32%的患者和54%的病灶出现完全缓解。单次治疗后，91%的患者和85%的病灶出现总体疾病反应。短期内未出现肝功能检查3级或更高程度的升高。
使用SIS进行的DEE-TACE在HCC患者中导致高于预期的初始反应。
